Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))

Aaron T. Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Ruben Mesa, Mark Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Geoffrey Chan, Moshe Talpaz

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret that there is an error in the email address of the corresponding author. Dr. Gerds' correct email address is gerdsa@ccf.org. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)105
Number of pages1
JournalLeukemia Research
Volume81
DOIs
StatePublished - Jun 2019
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))'. Together they form a unique fingerprint.

Cite this